Drugs for Speech Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 15)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dopamine |
Approved |
Phase 2, Phase 3 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
2 |
|
Ecopipam |
Investigational |
Phase 2, Phase 3 |
|
112108-01-7 |
|
3 |
|
Dopamine Agents |
|
Phase 2, Phase 3 |
|
|
|
4 |
|
Dopamine Antagonists |
|
Phase 2, Phase 3 |
|
|
|
5 |
|
Psychotropic Drugs |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Antipsychotic Agents |
|
Phase 2, Phase 3 |
|
|
|
7 |
|
Neurotransmitter Agents |
|
Phase 2, Phase 3 |
|
|
|
8 |
|
Botulinum Toxins |
|
Phase 1 |
|
|
|
9 |
|
Clotrimazole |
Approved, Vet_approved |
|
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-chloro-a,a-Diphenylbenzyl)imidazole
1-(O-chloro-alpha,alpha-Diphenylbenzyl)imidazole
1-(o-Chlorotrityl)imidazole
1-(O-Chlorotrityl)imidazole
1-(o-Chloro-α,α-diphenylbenzyl)imidazole
1-(O-chloro-α,α-diphenylbenzyl)imidazole
1-(α-(2-chlorophenyl)benzhydryl)imidazole
1-(α-(2-Chlorophenyl)benzhydryl)imidazole
117829-71-7
23593-75-1
33894_FLUKA
33894_RIEDEL
3ACDFDF8-38E3-4368-85D0-BDF8AE1E6591
AB00051951
AC1L1EIW
AC-279
B 5097
BAY 5097
Bay b 5097
BAY b 5097
Bay b 9057
BAY b5097
BAY-5097
Bay-B 5097
BAYb 5097
Bayer brand 1 OF clotrimazole
Bayer Brand 1 of Clotrimazole
Bayer brand 2 OF clotrimazole
Bayer Brand 2 of Clotrimazole
BIDD:GT0450
BIDD:PXR0036
Bio-0442
BPBio1_000126
BRN 0622318
BSPBio_000114
BSPBio_002057
C 6019
C06922
C22H17ClN2
C6019_SIGMA
Canesten
Canesten 1-day cream combi-pak
Canesten 1-Day Cream Combi-Pak
Canesten 1-day therapy
Canesten 1-Day Therapy
Canesten 3-day therapy
Canesten 3-Day Therapy
Canesten 6-day therapy
Canesten 6-Day Therapy
Canesten combi-pak 1-day therapy
Canesten Combi-Pak 1-Day Therapy
Canesten combi-pak 3-day therapy
Canesten Combi-Pak 3-Day Therapy
Canesten cream
Canesten Cream
Canesten solution
Canesten Solution
Canestene
Canestine
Canifug
CAS-23593-75-1
CCRIS 6245
CHEBI:3764
CHEMBL104
Chlotrimazole
CID2812
Cimitidine
Clomatin
Clotrimaderm
Clotrimaderm cream
Clotrimazol
Clotrimazol [INN-Spanish]
clotrimazole
Clotrimazole
Clotrimazole (JP15/USP/INN)
Clotrimazole [USAN:INN:BAN:JAN]
Clotrimazole schering brand
Clotrimazole Schering Brand
Clotrimazolum
Clotrimazolum [INN-Latin]
clotrimeizol
CPD000058306
CPD-8926
Cutistad
D00282
D003022
DB00257
Desamix F
DivK1c_000665
DRG-0072
EINECS 245-764-8
Empecid
Esparol
EU-0100315
FB 5097
FB b 5097
Fem care
Fem Care
FemCare
Gino-Lotremine
Gyne lotrimin
Gyne-lotrimin
Gyne-Lotrimin
Gyne-lotrimin 3
Gyne-Lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-Lotrimin 3 Combination Pack
Gyne-lotrimin combination pack
Gyne-Lotrimin Combination Pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
Gynix
HMS1568F16
HMS1920O21
HMS2051E11
HMS2091G10
HMS502B07
HSDB 3266
I01-3474
IDI1_000665
|
Kanesten
KBio1_000665
KBio2_001823
KBio2_004391
KBio2_006959
KBio3_001277
KBioGR_000850
KBioSS_001823
Klotrimazole
Lopac0_000315
Lopac-C-6019
Lotrimax
Lotrimin
Lotrimin (TN)
Lotrimin af
Lotrimin Af
Lotrimin af cream
Lotrimin AF Cream
Lotrimin af jock-itch cream
Lotrimin AF Jock-Itch Cream
Lotrimin af lotion
Lotrimin AF Lotion
Lotrimin af solution
Lotrimin AF Solution
Lotrimin cream
Lotrimin Cream
Lotrimin lotion
Lotrimin Lotion
Lotrimin solution
Lotrimin Solution
Lotrisone
LS-78271
MLS000028502
MLS000758243
MLS001423972
MolPort-002-557-756
mono-Baycuten
Monobaycuten
Mono-baycuten
Mycelax
Mycelex
Mycelex (TN)
Mycelex 7
Mycelex cream
Mycelex Cream
Mycelex g
Mycelex G
Mycelex otc
Mycelex OTC
Mycelex solution
Mycelex Solution
Mycelex troches
Mycelex Troches
Mycelex twin pack
Mycelex Twin Pack
Mycelex: mycosporinrimazole
Mycelex: MycosporinRimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-7 Combination Pack
Mycelex-g
Mycelex-G
myclo Cream
Myclo Cream
myclo Solution
Myclo Solution
myclo Spray solution
Myclo Spray Solution
myclo-Gyne
Myclo-Gyne
Mycofug
Mycosporin
Mykosporin
Nalbix
NCGC00015251-01
NCGC00015251-02
NCGC00015251-03
NCGC00015251-09
NCGC00093761-01
NCGC00093761-02
NCGC00093761-03
NCGC00093761-04
NCGC00093761-05
NCGC00093761-06
nchembio.65-comp9
nchembio790-comp30
NCIMech_000609
neo-Zol cream
Neo-Zol Cream
NINDS_000665
NSC 257473
NSC257473
Otomax
Pan-Fungex
Pedisafe
Prestwick_120
Prestwick0_000267
Prestwick1_000267
Prestwick2_000267
Prestwick3_000267
QTL1_000024
Rimazole
S1606_Selleck
SAM001247056
Schering brand OF clotrimazole
Schering Brand of Clotrimazole
SMR000058306
SPBio_000176
SPBio_002333
Spectrum_001343
SPECTRUM1500200
Spectrum2_000128
Spectrum3_000359
Spectrum4_000295
Spectrum5_000781
Stiemazol
STK700023
Tibatin
Trimysten
Trivagizole 3
UNII-G07GZ97H65
Veltrim
ZINC03807804
|
|
10 |
|
Miconazole |
Approved, Investigational, Vet_approved |
|
|
22916-47-8 |
4189 |
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
11 |
|
Silver sulfadiazine |
Approved, Vet_approved |
|
|
22199-08-2 |
441244 |
Synonyms:
(4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver
22199-08-2
481181_ALDRICH
4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
4-amino-N-pyrimidin-2-ylbenzenesulfonamide
Abbott Brand of Silver Sulfadiazine
AC-19319
AC1L1KQS
AC1L9ATF
AC1L9Q6O
AC1NUR63
AC1O8LAG
AC-3535
AKOS005111099
AKOS005111434
Aldo Brand of Silver Sulfadiazine
ARONIS23842
Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt
Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex
Brandiazin
C10H9N4O2S.Ag
CHEBI:9142
CHEMBL1200766
CID11947738
CID31011
CID441244
CID452254
CID5459124
D00433
D012837
DB05245
Dermazin
Dermazine
EINECS 244-834-5
Flamazine
Flammazine
Geben
I06-0145
I06-145
LS-147839
Major Brand of Silver Sulfadiazine
medphano Brand of Silver Sulfadiazine
MLS000069662
MolPort-003-934-423
MolPort-003-986-619
MolPort-006-395-987
Monarch Brand of Silver Sulfadiazine
N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt
N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt
NSC 625324
NSC625324
|
Par Brand 1 of Silver Sulfadiazine
Par Brand 2 of Silver Sulfadiazine
Par Brand 3 of Silver Sulfadiazine
Pharmascience Brand of Silver Sulfadiazine
Rhone Poulenc Rorer Brand of Silver Sulfadiazine
Rhone-Poulenc Rorer Brand of Silver Sulfadiazine
S0595
Sherwood Brand of Silver Sulfadiazine
Sicazine
Silbertone
Sildaflo
Silvadene
Silvadene (TN)
Silvederma
silver
silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide
silver sulfadiazinate
Silver sulfadiazinate
silver sulfadiazine
Silver sulfadiazine
Silver Sulfafdiazine
Silver sulphadiazine
silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide
Silver(I) sulfadiazine
Smith & Nephew Brand of Silver Sulfadiazine
SMR000059233
Solvay Brand of Silver Sulfadiazine
SSD
SSD (1% Silver Sulfadiazine Cream USP)
SSD AF
STL069502
Sulfadiazin silber
Sulfadiazin, silbersalz
Sulfadiazine silver
SULFADIAZINE SILVER
Sulfadiazine silver (JP15)
Sulfadiazine silver salt
Sulfadiazine silverSilvadene
Sulfadiazine, silver
Sulfadiazine, silver (USP)
Sulfadiazine, Silver [USAN]
Sulfafdiazine, Silver
Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt
Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt
Sulfargen
Thermazene
TL8001845
UNII-W46JY43EJR
Zenith Brand of Silver Sulfadiazine
|
|
12 |
|
Tacrolimus |
Approved, Investigational |
|
|
104987-11-3 |
445643 439492 6473866 |
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
13 |
|
Antifungal Agents |
|
|
|
|
|
14 |
|
Pharmaceutical Solutions |
|
|
|
|
|
15 |
|
Liver Extracts |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 59)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open-label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). |
Unknown status |
NCT02909088 |
Phase 2, Phase 3 |
Ecopipam 50mg;Ecopipam 100mg |
2 |
Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges |
Completed |
NCT02528006 |
Phase 2, Phase 3 |
|
3 |
Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy - Multicenter Double Blind Randomized and Controlled Trial |
Not yet recruiting |
NCT03676439 |
Phase 2, Phase 3 |
|
4 |
Left, Right, or Bilateral Thalamic Deep Brain Stimulation for Voice Tremor: A Prospective, Randomized, Double-Blinded Trial |
Unknown status |
NCT02960243 |
Phase 1, Phase 2 |
|
5 |
Word by Word: Building Sentences With Preschoolers Who Use AAC |
Recruiting |
NCT03538925 |
Phase 2 |
|
6 |
Speech-in-Noise Treatments to Improve Hypophonia in Everyday Social Contexts for Individuals With Parkinson's Disease |
Not yet recruiting |
NCT04323085 |
Phase 2 |
|
7 |
Biofeedback and Speech Disorders |
Completed |
NCT01905449 |
Phase 1 |
|
8 |
Laryngeal Resistance in Abductor Spasmodic Dysphonia |
Completed |
NCT00015795 |
Phase 1 |
|
9 |
Treating Speech Disorders in Patients With Parkinson's Disease Using Altered Auditory Feedback |
Completed |
NCT00488657 |
Phase 1 |
|
10 |
ASSIST: Child Apraxia Speech Treatment |
Recruiting |
NCT03903120 |
Phase 1 |
|
11 |
Influence of Medical Clowning in Videofluoroscopic Examination of Pediatric Speech Disorder |
Unknown status |
NCT02701322 |
|
|
12 |
Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison |
Unknown status |
NCT02753192 |
|
|
13 |
Effects of a Game-based Virtual Reality Video Capture Training Program Plus Occupational Therapy on Manual Dexterity in Patients With Multiple Sclerosis: a Randomizaed Controlled Trial |
Unknown status |
NCT03186612 |
|
|
14 |
Characteristics of Idiopathic Familial Speech Disorders |
Completed |
NCT00001551 |
|
|
15 |
Brain Activation During Developmental Speech Production and Speech Perception |
Completed |
NCT00004991 |
|
|
16 |
A Speech Disorders Severity Index to Measure the Impact of Oral and Pharyngeal Cavity on Speech Production |
Completed |
NCT02875795 |
|
|
17 |
Lingual Frenum and Possible Alterations in the Articulation of Phonemes |
Completed |
NCT01180309 |
|
|
18 |
Study of Speech Disorders , Voice and Swallowing in Primary Dystonia Oromandibular |
Completed |
NCT03380676 |
|
|
19 |
Visual Feedback of Tongue by Ultrasound Echography for Speech Trouble Rehabilitation |
Completed |
NCT02752425 |
|
|
20 |
Treatment Efficacy for Developmental Motor Speech Disorders: A PROMPT Randomized Control Trial |
Completed |
NCT02105402 |
|
|
21 |
Stuttering Severity and Anxiety in Egyptian School-age Children |
Completed |
NCT03160586 |
|
|
22 |
Intervention Software for Children With Speech Sound Disorders |
Completed |
NCT02490826 |
|
|
23 |
Constraint Induced Aphasia Therapy in Stroke Patients in Acute Stage. |
Completed |
NCT02804412 |
|
|
24 |
Development of Normative Ultrasound Databases of Tongue Surface Configuration |
Completed |
NCT00001218 |
|
|
25 |
Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering |
Completed |
NCT02288598 |
|
|
26 |
Age-related Correlates of Treatment Efficacy and Efficiency for Late-acquired Sounds |
Completed |
NCT03663972 |
|
|
27 |
Brain Connectivity Supporting Language Recovery in Aphasia |
Completed |
NCT02416856 |
|
|
28 |
Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx |
Completed |
NCT00001167 |
|
|
29 |
The Follow Study of Speech Functions in Preschool Children With Cerebral Palsy: Clinical Measures and Acoustic Analysis |
Completed |
NCT02378987 |
|
|
30 |
Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing |
Completed |
NCT01163331 |
|
|
31 |
Apraxia of Speech: A Comparison of EPG Treatment & Sound Production Treatment |
Completed |
NCT02554513 |
|
|
32 |
Les Cartes Sensori-motrices De La Parole : Corrélats Neuroanatomiques Des Systèmes De Perception Et De Production Des Voyelles Du Français |
Completed |
NCT00889317 |
|
|
33 |
Software for Alternative Communication |
Completed |
NCT02847923 |
|
|
34 |
Word-Retrieval for Aphasia: Facilitation of Generalization |
Completed |
NCT00125242 |
|
|
35 |
Evaluation of the Effects of Response Elaboration Training for Aphasia |
Completed |
NCT00125216 |
|
|
36 |
The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection |
Completed |
NCT00001448 |
|
|
37 |
Effect of Oral Motor Exercises and Breathing Exercises for Dysphagia in Parkinson Disease: Randomized Clinical Trial |
Completed |
NCT01420796 |
|
|
38 |
TeleRehab for Patients With Post-Stroke Communication Deficits Using Mobile Technology |
Completed |
NCT02615132 |
|
|
39 |
Static and Dynamic Balance Changes After a Scheduled Exercise Program in Children With Dyslexia |
Completed |
NCT04386161 |
|
|
40 |
REFIT Hearing: Remote Fitting of Hearing Aids |
Completed |
NCT02589561 |
|
|
41 |
The Effect of Different Feeding Methods and Non-nutritive Sucking Behaviours on Child Speech Development |
Recruiting |
NCT03315416 |
|
|
42 |
Auditory Profile and Language Development in Children Operated for Cleft Palate |
Recruiting |
NCT04367961 |
|
|
43 |
PROMPT to Improve Speech Motor Abilities in Preschool Children With Cerebral Palsy |
Recruiting |
NCT04189159 |
|
|
44 |
Botulinum Toxin for the Treatment of Neurological Disorders |
Recruiting |
NCT00001208 |
|
|
45 |
Augmenting Treatment Effects of Voice Therapy in Parkinson Disease |
Recruiting |
NCT02265315 |
|
|
46 |
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech |
Recruiting |
NCT03313011 |
|
|
47 |
The Role of Cerebellum in Speech |
Recruiting |
NCT03972202 |
|
|
48 |
Orthognathic Speech Pathology: Phonetic Contrasts of Patients With Dentofacial Discrepancies With Pre- and Post-Treatment Analyses |
Recruiting |
NCT04117360 |
|
|
49 |
Real World Testing of a Brain-Computer Interface to Operate a Commercial Augmentative and Alternative Communication System |
Recruiting |
NCT04026581 |
|
|
50 |
Efficacy of an Intervention for the Children With Severe Speech Sounds Disorders |
Recruiting |
NCT03700151 |
|
|
Cochrane evidence based reviews: speech disorders
|